The Cancer Research UK experience of pre-clinical toxicology studies to support early clinical trials with novel cancer therapies

This publication has 15 references indexed in Scilit:

• Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer
  British Journal of Cancer, 2004
• Multi-species toxicology approaches for oncology drugs
  European Journal Of Cancer, 2004
• Phase I Clinical Trial of Weekly Combretastatin A4 Phosphate: Clinical and Pharmacokinetic Results
  Journal of Clinical Oncology, 2003
• 5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study
  British Journal of Cancer, 2003
• A Phase I clinical and pharmacological study of cis-diamminedichloro(2-methylpyridine) platinum II (AMD473)
  British Journal of Cancer, 2003
• Hepatic Drug Targeting: Phase I Evaluation of Polymer-Bound Doxorubicin
  Journal of Clinical Oncology, 2002
• Phase I dose-escalation and pharmacokinetic study of a novel folate analogue AG2034
  British Journal of Cancer, 2001
• Revisions of general guidelines for the preclinical toxicology of new cytotoxic anticancer agents in Europe
  European Journal Of Cancer, 1995
• Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer
  Cancer Chemotherapy and Pharmacology, 1991
• General guidelines for the preclinical toxicology of new cytotoxic anticancer agents in Europe : Joint Steering Committee of the European Organization for Research and Treatment of Cancer (EORTC) and the Cancer Research Campaign (CRC)
  European Journal of Cancer and Clinical Oncology, 1990